Regulators enforce strict divide between topical and injectable exosomes

Clinicians must restrict exosomes to topical use or switch to polynucleotides.

As of 2026, no exosome product has received regulatory approval for injection, systemic administration, or implantation in the United States, the European Union, or other major regulatory jurisdictions, meaning clinics injecting these products face severe compliance and liability risks. Despite a 550 percent year-on-year surge in patient search interest, regulators draw a hard line at the stratum corneum.

In the European Union, topical exosome cosmeceuticals are classified as cosmetics under Regulation (EC) No 1223/2009. They remain compliant only if they are applied topically and the clinic avoids making therapeutic or structure-and-function medical claims. For clinics looking to utilize them legally, a 2026 systematic review of human studies found that topical exosomes, or those used as post-procedure adjuncts to microneedling and lasers, demonstrate promising short-term effects on hydration, elasticity, texture, pigmentation, and wrinkles over a 12-week period.

Formulations like Vitaran Exosome-PDRN Dual Serum, Vitaran Exosome PDRN Capsule Cream, and Vitaran Exosome PDRN Azulene (which incorporate CS-PDRN, Centella asiatica, NMN, and Azulene) fit this cosmetic profile. However, if patients demand an injectable regenerative option, clinicians in Europe should utilize CE-certified injectable polynucleotides (PDRN) like Plinest, Plinest Eye, Newest, or Lumi Eyes. These polynucleotide products serve as legally compliant, clinically validated alternatives that achieve regenerative goals without violating the strict regulatory ban on exosome injections.

Source: Hyashop, https://www.hyashop.com/blog/exosomes-aesthetic-medicine-2026-regulatory-landscape